Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jun 23, 2020
Aurora Cannabis (ACB, $13.73) to layoff 700 workers, close 5 facilities, and take $60 million charge

Aurora Cannabis (ACB, $13.73) to layoff 700 workers, close 5 facilities, and take $60 million charge

Aurora Cannabis announced that it was retrenching about 700 employees, and closing five production facilities. It is also taking a $60 million charge for the quarter ending June 30.

The layoffs include  an approximate 25% reduction in Aurora's SG&A [selling, general and administrative] staff, most with immediate effect, and an approximate 30% reduction in production staff over the next two quarters, according to the cannabis company’s statement.

Aurora plans to shutter operations at five facilities over the next two quarters ,in order to orient itself more towards production and manufacturing at the company's “larger scale and highly efficient sites”, as indicated in the company’s statement.

The company expects to record production asset impairment charges of up to $60 million for Q4 2020. It also expects to record a charge of up to $140 million in the carrying value of certain inventory.

Tickeron's AI-powered scorecard rates Aurora Cannabis a STRONG SELL.

ACB enters a Downtrend because Momentum Indicator dropped below the 0 level on June 05, 2020

This indicator signals that ACB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the ticker, shorting the ticker, or exploring put options. In 72 of 84 cases where ACB's Momentum Indicator fell below the 0 level, its price fell further within the subsequent month. The odds of a continued Downtrend are 86%.

Current price $13.65 crossed the support line at $13.19 and is trading between $14.63 resistance and $13.19 support lines. Throughout the month of 05/20/20 - 06/22/20, the price experienced a +8% Uptrend. During the week of 06/15/20 - 06/22/20, the stock enjoyed a +4% Uptrend growth.

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator appears to be shifting from an Uptrend to a Downtrend. In 24 of 40 cases where ACB's RSI indicator exited the overbought zone, the price fell further within the following month. The odds of a continued Downtrend are 60%.

The Moving Average Convergence Divergence (MACD) crossed below the signal line. In 34 of 42 cases where ACB's MACD histogram became negative, the price fell further within the following month. The odds of a continued Downtrend are 81%.

Bullish Trend Analysis

The Stochastic Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 219 of 266 cases, the price rose further within the following month. The odds of a continued Uptrend are 82%.

The lower Bollinger Band was broken -- a price increase is expected as the ticker heads toward the middle band, which indicates a buy or call consideration for traders. In 33 of 39 cases where ACB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

Tickeron has a positive outlook on this ticker and predicts a further increase by more than 4.00% within the next month with a likelihood of 59%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.69.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.55) is normal, around the industry mean (0.93). P/E Ratio (0.00) is within average values for comparable stocks, (29.45). Projected Growth (PEG Ratio) (0.00) is also within normal values, averaging (115.92). Dividend Yield (0.00) settles around the average of (1.00) among similar stocks. P/S Ratio (4.63) is also within normal values, averaging (10.69).

The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

Related Ticker: ACB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ACB sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for ACB moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where ACB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on ACB as a result. In 81 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

Following a +14.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 176 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 61 of 95 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.695) is normal, around the industry mean (43.873). P/E Ratio (19.440) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.13B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -5%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 22%. RGC experienced the highest price growth at 17%, while LQDA experienced the biggest fall at -62%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 44%. For the same stocks of the Industry, the average monthly volume growth was 55% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 84
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
ACB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a licensed producer of medical marijuana in Canada

Industry PharmaceuticalsGeneric

Industry
Pharmaceuticals Other
Address
90B Street SW
Phone
+1 855 279-4652
Employees
1028
Web
https://www.auroramj.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
GE Aerospace (GE) stock declined -12% over the past 30 days, falling from around $333 to $293, amid profit-taking after record highs near $348. Over the past quarter, the stock is down -8%, reflecting post-earnings selloff despite strong Q4 2025 results with 20% revenue growth.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
NBR stock rose approximately +12% over the last 30 days, driven by positive momentum in the oil and gas drilling sector and strong Q4 earnings beat. Over the past quarter, the stock surged +58%, fueled by robust YTD performance, debt reduction efforts, and improved operational results in international drilling.
Patterson-UTI Energy, Inc. (PTEN) stands out as a leading provider of drilling and completion services to oil and natural gas exploration and production companies, primarily in the United States and select international markets. The company operates through three main segments: Drilling Services, which includes contract drilling rigs and directional drilling; Completion Services, encompassing hydraulic fracturing, wireline, and pumping; and Drilling Products, offering specialized drill bits globally, including in the Middle East.
As a provider of onshore drilling and completion services, Patterson-UTI Energy (PTEN) is gearing up for a key Q1 2026 earnings report against the backdrop of fluctuating oil prices and steady U.S. rig demand. The company's integrated approach across Drilling Services, Completion Services, and Drilling Products gives it a solid footing in North American shale plays. In my view, recent quarters like Q4 2025, where revenue exceeded estimates despite a net loss, highlight its resilience. This upcoming report will offer insights into activity levels, margin trends, and capital discipline amid supply growth and geopolitical tensions. With strong free cash flow and recent dividend increases, PTEN's focus on shareholders stands out, making this a critical gauge for the 2026 outlook in the cyclical oilfield services sector.
When geopolitical turmoil sends markets into chaos, most retail traders freeze — but Tickeron's Energy (OXY, EOG, DVN, FANG, APA, MTDR) AI Trading Agent is built to thrive in exactly these conditions. This 15-minute and 60-minute AI-powered robot has delivered a +76.22% annualized return with a 64.21% win rate and a Profit Factor of 2.70 — trading six of the most volatile and opportunity-rich energy tickers on the market.
The global energy sector is on fire — literally and figuratively. With crude oil prices swinging 20–30% in response to geopolitical flashpoints, OPEC+ production cuts, and escalating conflicts in Eastern Europe and the Middle East, traders who aren't using AI-powered tools are flying blind. Enter Tickeron's Energy (Oil & Gas – E&P) AI Trading Agent — a 60-minute signal robot built exclusively around five high-impact Exploration & Production tickers, now posting a staggering +49% Annualized Return and +1,251% 30-Day Annualized Return, with $14,703 in closed-trade P&L on a $30,000 simulated balance.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
Aurora Cannabis (ACB, $13.73) to layoff 700 workers, close 5 facilities, and take $60 million charge